See more : Class Acceleration Corp. (CLAS) Income Statement Analysis – Financial Results
Complete financial analysis of MedinCell S.A. (MEDCL.PA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MedinCell S.A., a leading company in the Biotechnology industry within the Healthcare sector.
- Avalanche International, Corp. (AVLP) Income Statement Analysis – Financial Results
- Taiyuan Heavy Industry Co., Ltd. (600169.SS) Income Statement Analysis – Financial Results
- Fatfish Group Limited (FFTTF) Income Statement Analysis – Financial Results
- AIB Group plc (AIBG.L) Income Statement Analysis – Financial Results
- Shenzhen Special Economic Zone Real Estate & Properties (Group) Co., Ltd. (000029.SZ) Income Statement Analysis – Financial Results
MedinCell S.A. (MEDCL.PA)
About MedinCell S.A.
MedinCell S.A. develops various therapeutic solutions. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia; mdc-CWM, an intra-articular injection to treat pain and inflammation; and mdc-TJK, a subcutaneous injection in preclinical trials for use in the treatment of schizophrenia. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception; mdc-ANG for CNS related treatments; mdc-ELK for depression; and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. The company is based in Jacou, France.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.95M | 9.89M | 4.09M | 8.19M | 2.85M | 1.44M | 6.44M | 8.53M | 8.23M |
| Cost of Revenue | 2.79M | -3.77M | -4.25M | 1.45M | 969.00K | 1.01M | 218.00K | 885.00K | 332.00K |
| Gross Profit | 9.16M | 13.66M | 8.34M | 6.74M | 1.88M | 434.00K | 6.22M | 7.65M | 7.90M |
| Gross Profit Ratio | 76.68% | 138.08% | 203.86% | 82.27% | 66.02% | 30.08% | 96.61% | 89.63% | 95.97% |
| Research & Development | 21.08M | 26.67M | 22.44M | 18.51M | 16.20M | 11.98M | 8.85M | 7.55M | 5.96M |
| General & Administrative | 9.15M | 7.13M | 6.21M | 5.64M | 5.60M | 4.90M | 4.25M | 2.87M | 2.16M |
| Selling & Marketing | 2.64M | 2.59M | 2.27M | 1.80M | 2.36M | 2.68M | 1.89M | 1.38M | 752.00K |
| SG&A | 11.81M | 9.40M | 8.28M | 7.35M | 7.76M | 7.58M | 6.10M | 4.24M | 2.91M |
| Other Expenses | -2.75M | 0.00 | 0.00 | -20.00K | -99.00K | 15.95M | 4.67M | 2.84M | 1.85M |
| Operating Expenses | 30.14M | 36.06M | 30.72M | 25.88M | 24.06M | 15.95M | 13.52M | 10.39M | 7.81M |
| Cost & Expenses | 30.14M | 37.73M | 32.24M | 27.22M | 25.32M | 16.96M | 13.74M | 11.27M | 7.81M |
| Interest Income | 553.00K | 41.00K | 46.00K | 40.00K | 64.00K | 7.00K | 138.00K | 21.00K | 2.00K |
| Interest Expense | 4.62M | 3.93M | 1.84M | 3.58M | 2.12M | 2.13M | 1.85M | 1.31M | 127.00K |
| Depreciation & Amortization | 1.72M | 1.67M | 1.52M | 1.34M | 1.26M | 775.00K | 1.10M | 552.00K | 331.00K |
| EBITDA | -18.61M | -30.18M | -22.95M | -17.69M | -18.37M | -15.22M | -6.47M | -3.04M | 788.00K |
| EBITDA Ratio | -155.83% | -264.66% | -651.10% | -216.11% | -743.72% | -1,054.82% | -99.50% | -25.61% | 9.57% |
| Operating Income | -20.98M | -27.84M | -28.15M | -19.03M | -22.47M | -15.52M | -7.38M | -3.59M | 421.00K |
| Operating Income Ratio | -175.61% | -281.49% | -688.17% | -232.48% | -787.76% | -1,075.26% | -114.60% | -42.06% | 5.11% |
| Total Other Income/Expenses | -3.97M | -11.73M | -5.24M | -7.00M | -5.27M | -4.19M | -1.84M | -1.30M | -91.00K |
| Income Before Tax | -24.95M | -35.78M | -29.05M | -22.58M | -24.59M | -19.71M | -9.22M | -4.89M | 330.00K |
| Income Before Tax Ratio | -208.87% | -361.78% | -710.34% | -275.78% | -862.20% | -1,365.90% | -143.13% | -57.27% | 4.01% |
| Income Tax Expense | 88.00K | -3.77M | -4.25M | -3.59M | -675.00K | -28.00K | 360.00K | -1.35M | -255.00K |
| Net Income | -25.04M | -32.01M | -24.81M | -18.99M | -23.92M | -19.69M | -9.57M | -3.56M | 622.00K |
| Net Income Ratio | -209.61% | -323.69% | -606.50% | -231.93% | -838.53% | -1,364.31% | -148.66% | -41.73% | 7.56% |
| EPS | -0.88 | -1.27 | -1.00 | -0.86 | -1.19 | -1.14 | -0.66 | -0.25 | 0.04 |
| EPS Diluted | -0.88 | -1.27 | -1.00 | -0.86 | -1.19 | -1.14 | -0.66 | -0.25 | 0.04 |
| Weighted Avg Shares Out | 28.42M | 25.19M | 24.87M | 22.04M | 20.11M | 17.26M | 14.43M | 14.41M | 14.47M |
| Weighted Avg Shares Out (Dil) | 28.42M | 25.19M | 24.87M | 22.04M | 20.11M | 17.26M | 14.43M | 14.47M | 14.47M |
Source: https://incomestatements.info
Category: Stock Reports